Trump Slaps 100% Tariffs on Patented Drugs, New Duties on Metals
Trump Slaps 100% Tariffs on Patented Drugs, New Duties on Metals
The US imposes 100% tariffs on patented medicines and new duties on steel, aluminium, and copper to spur domestic production, amid warnings of higher costs and trade tensions.
The Trump administration has unveiled sweeping tariff measures, slapping 100% duties on imported patented medicines and introducing new duties on steel, aluminium, and copper. The stated aim is to push companies to manufacture more goods domestically, strengthening national security and shortening supply chains. Exemptions will apply to some nations, signaling a targeted approach rather than a blanket protectionist stance. The moves build on prior trade actions and reflect a tougher line on global commerce.
Analysts cautioned that while the policy could spur reshoring, it could also raise prices for patients and disrupt intricate pharmaceutical and manufacturing networks that span continents. Drugmakers may accelerate local production or diversify suppliers, but European and Asian partners could respond with their own measures, risking a cycle of retaliatory tariffs and further volatility in markets.
Critics argue the tariffs could undermine global collaboration on healthcare and access to life-saving therapies, particularly if exemptions are narrow or inconsistently applied. Supporters contend that strengthening domestic production reduces reliance on foreign supply and enhances resilience in critical sectors. As one year of related policies—often referred to in media commentary as Liberation Day measures—lingers in industry and government discourse, the administration has signaled that exemptions and timelines will be calibrated but has yet to publish full details.
Observers say the policy’s real test will come with how allies and trading partners respond, and whether the US can maintain political support for a strategy that ties national security to economic policy. Investors and manufacturers will be watching closely, awaiting further guidance on implementation, affected products, and transitional arrangements.
In the weeks ahead, regulatory filings, congressional feedback, and diplomatic negotiations are expected to shape the final contours of the tariff regime, as stakeholders weigh the balance between domestic job creation and potential costs to consumers and global supply chains.
